Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today)
Johnson & Johnson went a long way toward strengthening its oncology pipeline, agreeing to buy Cougar Biotechnology Inc. in a deal worth just under $1 billion. (BioWorld Today)
For cash-starved biotechs that have not yet found a parter or buyer, and are not in the running for any grant money or government contracts, there may be few options for survival in today's economy.
